$TRDA
Entrada Therapeutics, Inc. Stock $trda

$trda Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000168937523000039 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$18.17M	$25.26M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.169M	$7.938M	$6.433M
YoY Change	11.39%	23.39%
% of Gross Profit
Research & Development	$26.30M	$23.10M	$15.72M
YoY Change	61.87%	46.98%	152.58%
% of Gross Profit
Depreciation & Amortization	$730.0K	$500.0K	$400.0K
YoY Change	46.0%	25.0%	100.0%
% of Gross Profit
Operating Expenses	$34.47M	$31.04M	$22.15M
YoY Change	46.17%	40.13%	163.92%
Operating Profit	-$16.30M	-$5.780M	-$22.15M
YoY Change	-30.88%	-73.91%	163.92%
Interest Expense	$4.218M	$2.657M	$480.0K
YoY Change	946.65%	453.54%
% of Operating Profit
Other Income/Expense, Net	$4.218M	$2.657M	$480.0K
YoY Change	946.65%	453.54%	3592.31%
Pretax Income	-$12.08M	-$3.123M	-$21.67M
YoY Change	-47.88%	-85.59%
Income Tax	$13.85M	$3.600M	$0.00
% Of Pretax Income
Net Earnings	-$25.93M	-$6.674M	-$21.67M
YoY Change	11.86%	-69.2%	158.6%
Net Earnings / Revenue	-142.7%	-26.42%
Basic Earnings Per Share	-$0.78	-$0.21	-$0.69
Diluted Earnings Per Share	-$0.78	-$0.21	-$0.69
COMMON SHARES
Basic Shares Outstanding	33.20M shares	33.08M shares	31.25M shares
Diluted Shares Outstanding	33.16M shares	32.37M shares	31.25M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$376.8M	$411.6M	$263.9M
YoY Change	54.26%	55.98%
Cash & Equivalents	$79.74M	$227.6M	$84.64M
Short-Term Investments	$297.0M	$184.0M	$179.3M
Other Short-Term Assets	$9.662M	$16.21M	$8.810M
YoY Change	0.13%	83.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$390.2M	$434.1M	$272.7M
YoY Change	53.68%	59.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$99.30M	$9.394M	$7.197M
YoY Change	1175.53%	30.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.488M	$13.84M	$1.434M
YoY Change	412.91%	865.34%
Total Long-Term Assets	$103.8M	$41.43M	$43.99M
YoY Change	147.03%	-5.81%
TOTAL ASSETS
Total Short-Term Assets	$390.2M	$434.1M	$272.7M
Total Long-Term Assets	$103.8M	$41.43M	$43.99M
Total Assets	$494.0M	$475.6M	$316.7M
YoY Change	66.93%	50.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.422M	$6.474M	$2.931M
YoY Change	-47.6%	120.88%
Accrued Expenses	$14.51M	$11.68M	$4.524M
YoY Change	171.75%	158.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$125.9M	$147.6M	$15.43M
YoY Change	596.69%	856.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$161.1M	$98.36M	$23.89M
YoY Change	639.12%	311.82%
Total Long-Term Liabilities	$161.1M	$98.36M	$23.89M
YoY Change	639.12%	311.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$125.9M	$147.6M	$15.43M
Total Long-Term Liabilities	$161.1M	$98.36M	$23.89M
Total Liabilities	$287.1M	$246.0M	$39.31M
YoY Change	619.88%	525.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$220.9M	-$195.0M	-$115.3M
YoY Change	59.49%	69.12%
Common Stock	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$206.9M	$229.6M	$277.4M
YoY Change
Total Liabilities & Shareholders Equity	$494.0M	$475.6M	$316.7M
YoY Change	66.93%	50.16%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$25.93M	-$6.674M	-$21.67M
YoY Change	11.86%	-69.2%	158.6%
Depreciation, Depletion And Amortization	$730.0K	$500.0K	$400.0K
YoY Change	46.0%	25.0%	100.0%
Cash From Operating Activities	-$35.09M	$203.4M	-$20.99M
YoY Change	94.85%	-1068.98%	151.81%
INVESTING ACTIVITIES
Capital Expenditures	$1.522M	$1.668M	$594.0K
YoY Change	-296.39%	180.81%	-34.58%
Acquisitions
YoY Change
Other Investing Activities	-$111.7M	-$38.78M	-$180.9M
YoY Change	-546.94%	-78.57%
Cash From Investing Activities	-$113.3M	-$40.44M	-$181.5M
YoY Change	-567.52%	-77.72%	19892.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	443.0K	$19.54M	$50.00K
YoY Change	3927.27%	38972.0%	-99.96%
NET CHANGE
Cash From Operating Activities	-35.09M	$203.4M	-$20.99M
Cash From Investing Activities	-113.3M	-$40.44M	-$181.5M
Cash From Financing Activities	443.0K	$19.54M	$50.00K
Net Change In Cash	-147.9M	$182.5M	-$202.5M
YoY Change	-2475.22%	-190.13%	-288.98%
FREE CASH FLOW
Cash From Operating Activities	-$35.09M	$203.4M	-$20.99M
Capital Expenditures	$1.522M	$1.668M	$594.0K
Free Cash Flow	-$36.61M	$201.7M	-$21.59M
YoY Change	112.45%	-1034.59%	133.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001689375
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40969
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ENTRADA THERAPEUTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3983399
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	One Design Center Place
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 17-500
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02210
CY2023Q1	dei	City Area Code CityAreaCode	857
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	520-9158
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	TRDA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33197018	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227648000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45157000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	183983000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	143555000	usd
CY2023Q1	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	6297000	usd
CY2022Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16207000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21163000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	434135000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	209875000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9394000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7681000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14247000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	25340000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13843000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5210000	usd
CY2023Q1	us-gaap	Assets Assets	475569000	usd
CY2022Q4	us-gaap	Assets Assets	252056000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6474000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5990000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11676000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7576000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7103000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8406000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	122341000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	147594000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21972000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9122000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17530000	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	89241000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2023Q1	us-gaap	Liabilities Liabilities	245957000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	39502000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33177324	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33133736	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31448508	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31394767	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	425210000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	402893000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-642000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2057000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194959000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-188285000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	229612000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	212554000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	475569000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	252056000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25260000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23102000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15718000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7938000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6433000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	31040000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	22151000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5780000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22151000	usd
CY2023Q1	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	2657000	usd
CY2022Q1	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	480000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2657000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	480000	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-3123000	usd
CY2022Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-21671000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3551000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6674000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21671000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32374299	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32374299	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31246916	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31246916	shares
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1415000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1535000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1415000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1535000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5259000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23206000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298718000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000	usd
CY2022Q1	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	35000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1794000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1535000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21671000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	277391000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	212554000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	129000	usd
CY2023Q1	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	26000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19407000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2755000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1415000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6674000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	229612000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-6674000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-21671000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	541000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	390000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2755000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1794000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	237000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-142000	usd
CY2023Q1	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	6297000	usd
CY2022Q1	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	0	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4339000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1670000	usd
CY2023Q1	trda	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-3332000	usd
CY2022Q1	trda	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-1582000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8633000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	562000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	534000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2061000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4107000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1526000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1950000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1531000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	211582000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	203399000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20991000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1668000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	594000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	101776000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	182653000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	63000000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1714000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40444000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181533000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19407000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	129000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000	usd
CY2023Q1	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	26000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19536000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	182491000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-202474000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49107000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291064000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231598000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88590000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	57000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	391000	usd
CY2023Q1	trda	Right Of Use Asset Surrendered As Part Of Lease Modification RightOfUseAssetSurrenderedAsPartOfLeaseModification	7761000	usd
CY2022Q1	trda	Right Of Use Asset Surrendered As Part Of Lease Modification RightOfUseAssetSurrenderedAsPartOfLeaseModification	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	32991000	usd
CY2023Q1	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	617000	usd
CY2022Q1	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	495000	usd
CY2022Q1	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	35000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6700000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21700000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	411600000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231598000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49107000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227648000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45157000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	125576000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	124445000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent	59049000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	59538000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	184625000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	556000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1198000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	183983000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	142170000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	140237000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent	3442000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	3318000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	145612000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2057000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	143555000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	23	security
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	95200000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	900000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	600000	usd
CY2023Q1	us-gaap	Cash Cash	300000	usd
CY2022Q4	us-gaap	Cash Cash	300000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13234000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10982000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3840000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3301000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9394000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7681000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	500000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	400000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2049000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5063000	usd
CY2023Q1	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	4057000	usd
CY2022Q4	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	1157000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	837000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	925000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3551000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1182000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	431000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11676000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7576000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.39
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	11736	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13.69
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9494909	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8032687	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2755000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1794000	usd
CY2023Q1	trda	Stock Issued During Period Shares Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions	43588	shares
CY2022	trda	Stock Issued During Period Shares Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions	53741	shares
CY2023Q1	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	200000	usd
CY2022Q4	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	200000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5028850	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.95
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	350396	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.24
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18344	shares
CY2022	trda	Operating Lease Expense Monthly OperatingLeaseExpenseMonthly	500000	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	800000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5349166	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.04
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2878389	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.37
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3600000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	3665000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	3665000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2282000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0795
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6627000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5741000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5396000	usd
CY2023Q1	trda	Lessee Operating Lease Liability To Be Paid Due After Year Three LesseeOperatingLeaseLiabilityToBePaidDueAfterYearThree	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17764000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1539000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	16225000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P10Y
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Renewal Term1 LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1	P5Y
CY2022Q1	trda	Operating Leases Rental Expenses Initial Fixed Monthly Rental Payments First12 Months OperatingLeasesRentalExpensesInitialFixedMonthlyRentalPaymentsFirst12Months	500000	usd
CY2022Q1	trda	Number Of Square Feet In Lease Agreement NumberOfSquareFeetInLeaseAgreement	65000	sqft
CY2022Q1	trda	Operating Leases Rental Expenses Annual Increase OperatingLeasesRentalExpensesAnnualIncrease	0.03
CY2022Q1	trda	Tenant Improvements Allowance TenantImprovementsAllowance	19500000	usd
CY2022Q1	trda	Initial Fixed Rental Income Per Rentable Square Foot Of Premises Per Annum InitialFixedRentalIncomePerRentableSquareFootOfPremisesPerAnnum	240.00
CY2022Q1	trda	Operating Leases Additional Allowance OperatingLeasesAdditionalAllowance	1600000	usd
CY2022Q1	trda	Tenant Allowance Rentable Square Foot Of Premises Per Annum TenantAllowanceRentableSquareFootOfPremisesPerAnnum	20.00
CY2022Q1	trda	Interest Rate For Additional Improvements Allowance InterestRateForAdditionalImprovementsAllowance	0.08
CY2022Q1	trda	Lessee Operating Lease Level Direct Reduction Basis Term LesseeOperatingLeaseLevelDirectReductionBasisTerm	P120M
CY2023Q1	trda	Lessee Operating Lease Reimbursable Improvement Costs Incurred LesseeOperatingLeaseReimbursableImprovementCostsIncurred	21200000	usd
CY2023Q1	trda	Lessee Operating Lease Reimbursed Costs LesseeOperatingLeaseReimbursedCosts	14400000	usd
CY2023Q1	trda	Prepaid Rent Noncurrent PrepaidRentNoncurrent	13300000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Lease Not Yet Commenced Term Of Contract1 LessorOperatingLeaseLeaseNotYetCommencedTermOfContract1	P3Y
CY2022Q4	trda	Lessor Operating Lease Lese Not Yet Commenced Extension LessorOperatingLeaseLeseNotYetCommencedExtension	P6M
CY2022Q4	trda	Lessor Operating Lease Lese Not Yet Commenced Monthly Payments To Be Received LessorOperatingLeaseLeseNotYetCommencedMonthlyPaymentsToBeReceived	200000	usd
CY2022Q4	trda	Sublease Interest Rate Increase Per Annum Percent SubleaseInterestRateIncreasePerAnnumPercent	0.03
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	500000	usd
CY2023Q1	trda	Strategic Collaboration And License Agreement Term Of Contract StrategicCollaborationAndLicenseAgreementTermOfContract	P4Y
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6674000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21671000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32374299	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32374299	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31246916	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31246916	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6064062	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4806953	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001689375-23-000039-index-headers.html	Edgar Link	pending
0001689375-23-000039-index.html	Edgar Link	pending
0001689375-23-000039.txt	Edgar Link	pending
0001689375-23-000039-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trda-20230331.htm	Edgar Link	pending
trda-20230331.xsd	Edgar Link	pending
trda-20230331x10qex311.htm	Edgar Link	pending
trda-20230331x10qex312.htm	Edgar Link	pending
trda-20230331x10qex321.htm	Edgar Link	pending
trda-2023331x1016.htm	Edgar Link	pending
trda-2023331x1017.htm	Edgar Link	pending
trda-2023331x1018.htm	Edgar Link	pending
trda-20230331_def.xml	Edgar Link	unprocessable
trda-20230331_lab.xml	Edgar Link	unprocessable
trda-20230331_pre.xml	Edgar Link	unprocessable
trda-20230331_htm.xml	Edgar Link	completed
trda-20230331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRDA
Entrada Therapeutics, Inc. Stock $trda

2023 Q2 Form 10-Q Financial Statement

#000168937523000039 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA Entrada Therapeutics, Inc. Stock $trda

2023 Q2 Form 10-Q Financial Statement

#000168937523000039 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA
Entrada Therapeutics, Inc. Stock $trda